BioTuesdays
Feature

3DS’ genomic imaging for precision medicine

By Len Zehr As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging...

May 2, 2017
Feature

Vyome completing enrollment in acne POC trial

By Len Zehr Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial of its lead molecule for drug-resistant acne, VB 1953. “Our product has the potential to be...

March 21, 2017
Feature

Histogenics to complete Phase 3 enrollment in Q2

By Len Zehr Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee...

March 14, 2017
Feature

Arch moving to regulatory stage this year

By Len Zehr Arch Therapeutics (OTCQB:ARTH) has multiple regulatory filings planned in the U.S. and Europe this year for its AC5 Topical Hemostatic Device as the biopharma company shifts to regulatory-stage footing ahead...

March 7, 2017
Feature

Jaguar, Napo merger set for transformative growth

By Len Zehr The proposed merger of Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals is expected to create a combined company with prescription product revenue, potential line extensions and an...

February 28, 2017
Feature

In conversation with Chiara Russo

By Len Zehr As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it...

February 14, 2017
Feature

IntelGenx sees 2017 milestones as transformational

By Len Zehr IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry...

February 7, 2017
Feature

Iridex MicroPulse probes glaucoma continuum of care

By Len Zehr Iridex’s (NASDAQ:IRIX) flagship Cyclo G6 platform for the treatment of glaucoma utilizes a proprietary method of delivering laser therapy, known as MicroPulse, and disposable probes across the continuum of...

January 31, 2017
Feature

BioTime leading advances in regenerative medicine

By Len Zehr BioTime (NYSE:MKT, TASE:BTX) has multiple data milestones scheduled this year in its two lead regenerative medicine programs: OpRegen in dry AMD and Renevia in facial aesthetics. “We believe we are one of...

January 24, 2017
Feature

Arbutus taking multi-faceted approach to HBV

By Len Zehr Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with...

January 17, 2017
Feature

In conversation with Mohit Trikha

By Len Zehr As chief scientific officer, EVP and head of closely held Triphase Accelerator, Mohit Trikha has parlayed a successful 20-year track record in oncology drug development into a home run, selling Triphase’s...

January 3, 2017
Feature

In conversation with Jason Kolbert

By Len Zehr As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in...

November 22, 2016
Feature

In conversation with Dr. Chad Larson

By Len Zehr As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of...

November 15, 2016
Feature

Enumeral pursuing near-term collaborations

By Len Zehr Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and...

November 8, 2016